Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
384 results about "Effective drug concentration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti entity tumour medicinal composition containing platinum compound
InactiveCN1686554AAntineoplastic agentsPharmaceutical active ingredientsWhole bodyTherapeutic effect
A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer components (Pt compound and its synergist choosen from taxol-type anticancer medicine, antineoplastic antibiotic and antimetabolitic medicine), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Anti entity tumour medicinal composition
InactiveCN1686553AAntineoplastic agentsPharmaceutical active ingredientsWhole bodyTherapeutic effect
A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer component (plant alkaloid and its symergist chosen from taxol-type anticancer medicine, antineoplastic antibiotic and antimetabolitic), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Pharmaceutical composition for prevention or treatment of fibrotic diseases and application thereof
The invention discloses application of nintedanib, its salt and solvate in preparation of drugs for prevention or treatment of fibrotic diseases and a pharmaceutical composition for prevention or treatment of fibrotic diseases. The pharmaceutical composition comprises an active component and excipients, wherein the active component is selected from one or more of nintedanib, its salt and solvate. The nintedanib preparation provided by the invention can achieve treatment or prevention of fibrotic diseases on VEGF, PDGF and FGF angiogenesis receptors, and can provide an effective drug concentration, thus reaching a good control effect.
Owner:REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Antientity tumour medicinal composition containing topoenzyme inhibitor
A composite medicine for treating tumor by locally putting it in the tumor is composed of the active anticancer components (topoenzyme inhibitor and its symergist chosen from taxol-type anticancer medicnie, antineoplastic antibiotic and antimetabolitic medicine) and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Anti entity tumour medicinal composition containing tetrazine kind compound
A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer component (tetraazine compound and its synergist chosen from taxol-type anticancer medicine, antineoplastic antibiotic and antibetabolitic medicine), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Anti solid tumor medicine composition
InactiveCN1628850AImprove anti-cancer effectInhibitory activityAntineoplastic agentsPharmaceutical active ingredientsHydroxylamineAdjuvant
Disclosed is an anti solid tumor medicine composition, which comprises medicinal adjuvant and DNA restoring enzyme inhibitor and / or Nitrosoureas anti-cancer drugs, wherein the DAN restoring enzyme inhibitor is selected from methoxamine, hydroxylamine and their analogues, which can effectively destroy the DNA restoring function in the tumor cells, and lower the survivability of tumor cell to Semustine anti-cancer drugs and their analogues, the medicinal adjuvant is biological compactable, degradable and absorbing macromolecular polymer, which can slowly release the DNA restoring enzyme inhibitor onto tumor partially during the degradation and absorption process, thus the whole body toxicity reaction is reduced appreciably , and the effective medicinal concentration can be sustained to the tumor partially. By dispensing the composition to the tumor partially, the whole body toxicity reaction of Nitrosoureas anti-cancer drugs and / or DNA restoring enzyme inhibitor can be lowered, selectively increase the tumor local medicinal concentration, and the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can be improved.
Owner:南京天一药业有限公司
Anticarcinogenic internal implant agent
InactiveCN1679950APharmaceutical delivery mechanismAmide active ingredientsTreatment effectWhole body
An anticancer in vivo implant applied locally is prepared from the anticancer nitrosourea-type medicine, the anticancer synergist chosen from nitrogen mustard compound, mitotic inhibitor and antimetabolic anticancer medicine, and the biocompatible and biodegradable high-molecular polymer as medicinal additive.
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Anti-cancer medicine composition
The invention provides an anti-cancer medicine composition, with comprises medicinal adjuvant and DNA restoring enzyme inhibitor containing effective anticancer constituents, wherein the DNA restoring enzyme inhibitor is selected from poly (ADP-ribose) poly enzyme inhibitor and / or DNA-dependent protein kinase inhibitor, which can effectively destroy the DNA restoring function in the tumor cells, and lower the survivability of tumor cell to Nitrosoureas anti-cancer drugs and their analogues, and the medicinal adjuvant mainly comprises biological compactable, degradable and absorbing macromolecular polymers, which can slowly release the DNA restoring enzyme inhibitor onto tumor partially during the degradation and absorption process, thus the whole body toxicity reaction is reduced appreciably , and the effective medicinal concentration can be sustained to the tumor partially. The anti-cancer medicinal composition also contain Nitrosoureas anti-cancer drugs and their analogues, by dispensing the composition to the tumor partially, the whole body toxicity reaction of Nitrosoureas anti-cancer drugs and / or DNA restoring enzyme inhibitor can be lowered, and the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can be improved.
Owner:南京天一药业有限公司
Tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system, as well as preparation method and application thereof
InactiveCN104174027APromote endocytosisIncrease effective drug concentrationOrganic active ingredientsHeavy metal active ingredientsSide effectTreatment effect
The invention relates to a tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system, as well as a preparation method and application thereof. The tumor vessel-tumor cell membrane-cell nucleus continuous targeted drug delivery system comprises mesoporous silica nano-particles, RGD polypeptide which is linked to the surfaces of the mesoporous silica nano-particles in a covalent manner and serves as a tumor vessel / tumor cell membrane targeting ligand, and a nuclear localization signal polypeptide sequence serving as a cell nucleus targeting ligand. Under the condition of intravenous injection, the drug-loaded system can be enriched in a tumor tissue by means of the targeting effect of the tumor vessel to reduce the uptake of normal tissues and reduce toxic and side effect, is capable of increasing the phagocytosis amount of tumor cells by means of the identification effect on the tumor cell membrane, and can be used for directly delivering anti-cancer drugs into a cell nucleus by means of the delivery performance of the cell nucleus to increase the concentration of effective drugs, so that an optimal treatment effect can be achieved.
Owner:SHANGHAI INST OF CERAMIC CHEM & TECH CHINESE ACAD OF SCI
Combination of slow released anticancer medication
InactiveCN1660437AAddress sensitivityOvercoming toxicityAntineoplastic agentsPharmaceutical active ingredientsWhole bodyTherapeutic effect
A slowly-releasing anticancer composite medicine is composed of the hormone-kind anticancer medicine chosen from steroid-type hormone and hormone antagon for regulating the cell reproduction of hormone dependent tumor and the medicinal additive chosen from biocompatible and biodegradable high-molecular polymer for slowly releasing said anticanser medicine toward tumor.
Owner:SHANDONG LANJIN PHARMA +1
Slow-release preparation containing beta-lactamase inhibitor and cephalosporin and its use
The present invention relates to a slow-released preparation containing beta-lactamase inhibitor and cephalosporin. Said slow-released preparation can be made into antibiotic slow-released injection or slow-released implant preparation. Said injection is formed from slow-released microsphere and solvent, the slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor with antibacterial effective dose and cephalosporin, the solvent is special one containing suspension adjuvant of carboxymethyl cellulose sodium, etc. and its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C). The slow-released auxiliary material is selected from EVAc, polylactic acid copolymer, sebacic acid copolymer, albumin glue and gelatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application method. and can obtain obvious therapeutic effect for curing various infective diseases.
Owner:JINAN SHUAIHUA PHARMA TECH
Merariveron sustained-release tablet and preparation method thereof
InactiveCN103655503AGood curative effectImprove complianceOrganic active ingredientsPharmaceutical delivery mechanismSustained Release TabletAdhesive
The invention discloses a merariveron sustained-release tablet and a preparation method thereof. The merariveron sustained-release tablet is prepared from the following raw materials in percentage by weight: 5- 20% of merariveron, 10-70% of a skeleton material, 1- 5% of an antioxidant, 0.1-5% of a lubricant, 0-70% of a filler and a proper amount of an adhesive. The merariveron sustained-release tablet adopts a film coating, and thus the stability of the merariveron sustained-release tablet is improved. The sustained-release materials in the merariveron sustained-release tablet reduce influences, on release, of different PH valves. The influences, on the absorption of the merariveron sustained-release tablet, of food, are reduced, long-time stable effective drug concentration is kept, and thus the curative effect of the merariveron sustained-release tablet is improved. A patient only needs to take the merariveron sustained-release tablet once a day; the compliance of the patient is improved.
Owner:BEIJING RUNDEKANG MEDICAL TECH CO LTD
Anti-cancer medicine composition
InactiveCN1616099AAntineoplastic agentsPharmaceutical active ingredientsWhole bodyTherapeutic effect
The present invention relates to an anticancer medicine composition and belongs to the field of medicine technology. The anticancer medicine composition contains topomerase inhibitor and medicinal supplementary material. The topomerase inhibitorcan inhibit intracellular DNA repair function and reduce the tolerance one tumor cell on anticancer nitrosourea medicine; and the medicine supplementary material is mainly degradable biocompatible polymer. During the degrading and absorption process of the supplementary material, the anticancer medicine is released slowly to the tumor part, and this can lower the systemic toxic reaction while maintaining local effective medicine concentration. The anticancer medicine composition contains also anticancer nitrosourea medicine, and is set to the tumor part locally to enhance the treatment effect.
Owner:孔庆忠
Guanidine hydrochloride sustained release preparation and preparation method thereof
ActiveCN102579381AImprove stabilitySimple manufacturing processOrganic active ingredientsGranular deliveryBlood drug concentrationTableting
The invention discloses guanidine hydrochloride sustained release preparation and a preparation method thereof. The guanidine hydrochloride sustained release preparation is mainly prepared by guanidine hydrochloride, a filling agent, sustained release materials and potential of hydrogen (pH) sensitive materials. The preparation method comprises the steps of firstly preparing all raw materials according to proportion, evenly mixing the guanidine hydrochloride, the filling agent, the sustained release materials and the pH sensitive materials at high speed, granulating and drying the evenly mixed powder, finally adding a flow agent, a lubrication agent and an adhesion agent, tableting according to a general method, and achieving guanidine hydrochloride sustained release tablets. The guanidine hydrochloride sustained release preparation is small in side effect, obviously reduces difference of preparation of different batches, improves stability of samples, is convenient long term curing of patients and improves compliance of medicine. A patient can take the guanidine hydrochloride sustained release tablets once a day, so that effective drug concentration in bodies can be guaranteed for 24 hours, and nervous centralis side reactions caused by the fact that a blood concentration peak value is high due to general preparation is reduced.
Owner:ZHONGSHUAI PHARMA SCI & TECH CO LTD
Pharmaceutical composition for solid tumour
InactiveCN1634017AImprove anti-cancer effectIncrease and prolong concentrationAntineoplastic agentsHeavy metal compound active ingredientsTreatment effectAdjuvant
Disclosed is a pharmaceutical composition for solid tumour which comprises anticancer available composition and medicinal adjuvant, the anticancer available composition is platinum compounds, and the medicinal adjuvant mainly employs biological compactable, degradable and absorbable macromolecular polymer. The composition can lower down the whole body toxicity reaction of the medicament when locally dispensing on the tumor, selectively increase the tumor local medicinal concentration, and improve the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation.
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Composite medicine coating balloon, preparation method thereof, and composite medicine coating balloon dilatation catheter
The invention discloses a composite medicine coating balloon. The composite medicine coating balloon comprises a balloon body and a composite medicine coating covering the surface of the balloon body,wherein the composite medicine coating comprises a bottom-layer coating, a middle-layer coating and an outer-layer coating; the bottom-layer coating is used for coating the surface of the balloon body, and consists of medicines A and a hydrophilic excipient; the middle-layer coating consists of a medicine B packed with a packing agent and hydrophilic excipients / lipophilic excipients / amphipathic excipients; and the outer-layer coating consists of a medicine C and lipophilic excipients / amphipathic excipients. The invention further discloses a preparation method of the composite medicine coatingballoon and a composite medicine coating balloon dilatation catheter. According to the composite medicine coating balloon, the loss of traditional Chinese medicines in the balloon transporting process can be reduced, besides, the vasculopathy position can have effective medicine concentration within a short term, vascular restenosis is restrained, long-time medicine release can be provided, durable medicine action time can be maintained, and the restenosis rate can be reduced.
Owner:KOSSEL MEDTECH SUZHOU
Solid tumor treating medicine composition
The present invention is solid tumor treating medicine composition and belongs to the field of medicine technology. The medicine composition contains melphalan in effective anticancer amount and medicinal supplementary material. The medicinal supplementary material is mainly biocompatible, degradable and absorbable polymer, and during the degradation and absorption of the polymer, melphalan is released slowly to local tumor part to lower the systemic toxic reaction and to maintain local medicine concentration. The present invention has enhanced treating effect. The solid tumor includes cerebral tumor, liver cancer, lung cancer, esophagus cancer, gastric cancer, etc.
Owner:DASEN BIOLOGICAL PHARMA CO LTD
In-vivo gel preparatino able to be dropped in eyes and its preparing process
InactiveCN1397272ALow toxicityLess irritatingSenses disorderPharmaceutical delivery mechanismTreatment effectIrritation
An eyedrops able to become gel after it is dropped in eye for treating bacterial conjuctivities, keratitis, keratohelcosis, dacryocystitis, etc is prepared from antibacterial infilammatino-relieving medicine, thickening agent, antiseptic, isotonic regulator, pH regulator and water. Its advantages are long stay time in eye, high curative effect, and low poison and irritation.
Owner:SHANGHAI XINGKANG PHARMA RES & DEV
Anticancer combination of medication
InactiveCN1660436AAddress sensitivityOvercoming toxicityAntineoplastic agentsPharmaceutical active ingredientsWhole bodyTherapeutic effect
An anticancer composition medicine is composed of the antimitosis medicine for suppressing the reproduction of tumor cells and the medicinal additive chosen from the biocompatible and biodegradable high-molecular polymer for slowly releasing said antimitosis medicine toward the tumor.
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Long-acting slow release preparation for treating keratomycosis as well as preparation method and application thereof
ActiveCN104940936AHigh drug loadingFormulation stabilityOrganic active ingredientsSenses disorderAntifungalSide effect
The invention relates to a preparation for treating treating keratomycosis, and particularly relates to a long-acting slow release preparation for treating keratomycosis as well as a preparation method and application thereof. The substrate of the long-acting slow release preparation is formed through electrostatic bonding of a graphene material and a drug-carried chitosan material, drugs are carried on the sheet structure of the graphene material, the structure is stable, and the loading rate is high. The preparation provided by the invention has excellent bacteriostatic activity on fungus and bacterium, and is excellent in cytocompatibility, toughness, and tensile strength. The preparation can be simply and conveniently applied onto cornea, and has no toxic effects on normal tissue while achieving excellent bacteriostatic activity. The long-acting slow release preparation is taken as a dosage form in ophthalmology, can be adhered onto a cornea of a patient for long-acting slow release, so as to achieve effective drug concentration, and the preparation has the advantages that the preparation is simple and convenient, the drug-carried material self is excellent in bacteriostatic activity and mechanical property, stimulation and toxic or side effects on orbital tissue can be avoided, and the use is convenient.
Owner:SOUTH CHINA AGRI UNIV
Anti-cancer medicine composition containing antimetabolite
InactiveCN1634584AAntineoplastic agentsHeterocyclic compound active ingredientsWhole bodyTherapeutic effect
An anticancer pharmaceutical composition composed of pharmaceutic adjuvant and anti-metabolism medicine is disclosed. Wherein, the anti-metabolism medicine can effectively destroy DNA and / or protein synthesis and repairing function inside the tumor cell so as to inhibit the tumor cell growth, while the pharmaceutic adjuvant can mainly be biological compatible, degradable and absorbable macromolecule polymer, which can make the anti-metabolism drug to release slowly in the local tumor region in the degradation and absorption process, therefore it can both decrease considerably the whole body toxic reaction and sustain the local tumor effective drug level.
Owner:DASEN BIOLOGICAL PHARMA CO LTD
Neratinib sustained-release implant for treating solid tumor
InactiveCN101185633AOrganic active ingredientsPharmaceutical delivery mechanismProstate cancerTherapeutic effect
A sustained release implant includes 0.1%-50% (w / w) nilotinib, 50-99% sustained release excipients and 0-15% sustained release moderator. Sustained release excipients are mainly one or combination of poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co- phosphoric acid propyl), polylactic acid, the copolymer of polylactic acid and hydroxyacetic acid and polifeprosan; sustained release moderator is one or combination of mannitol, sorbic alcohol and chondroitin; sustained release implant applied in local tumor can slowly release nilotinib onto local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction; the invention not only reduces overall toxic reaction of nilotinib, but also selectively improves drug concentration in local tumor, enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy. The implant can be used for treating solid tumors including lung cancer, esophageal carcinoma, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic carcinoma, pancreatic cancer, bladder carcinoma, cerebroma, and colorectal cancer.
Owner:SHANDONG LANJIN PHARMA +1
Use of baicalein as antifungal medicine synergist
InactiveCN101066263AClear synergyReduce doseAntibacterial agentsOrganic active ingredientsBaicaleinTreatment effect
The present invention relates to medicine technology and is especially new use of baicalein, which is one kind of effective components extracted from skullcap root and has been used in treating various kinds of inflammation, as antifungal medicine synergist. Baicalein is added into antifungal pyrrole medicine in the added amount of 4-16 mcg / ml. Experiments show that adding baicalein into antifungal medicine of fluconazole, ketocanazole, miconazole, etc can ensure the treating effect on fungal inflection and resist the drug tolerance of drug resisting fungi, so that baicalein may be used as the synergist of antifungal medicine.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
GDNF-carrying microbubble preparation and method for making the same
ActiveCN102657612AThrough highIncrease effective drug concentrationNervous disorderPeptide/protein ingredientsDiseaseNeurotrophic factors
The invention discloses a GDNF-carrying microbubble preparation and a method for making the same. The GDNF-carrying microbubble is composed of a lipid bilayer internally wrapping biological inert gas and biotinylated GDNF connected to the outside of the lipid bilayer. Employing MRI real-time guided low-frequency focused ultrasound combined with BBB opening by the GDNF-carrying microbubble to irradiate a craniocerebral parietal cortex area of a rat (the optimal parameters are set to be: probe frequency 1 Hz, microbubble 0.5 mL, irradiation period 60 s, sound pressure 0.8 MPa, and time-delay 60s) can promote GDNF to penetrate the BBB and increase the effective drug concentration of GDNF in the central nervous system. The pharmacological research after effective macromolecule breaking through of BBB by low-frequency focused ultrasound combined with target microbubble technique will further increase the advantage of neurotrophic factors in treatment of brain diseases and provide the scientific evidence for GDNF to treat nervous centralis diseases.
Owner:PEKING UNIV
Drug-coating balloon catheter and production method and application thereof
ActiveCN107362439ANot easy to wash offHigh drug loading efficiencyBalloon catheterMedical devicesDrugs solutionDrug crystals
The invention provides a drug-coating balloon catheter and a production method and application thereof. The method includes: preparing active drug seed crystals, and screening the seed crystals 1-3 micrometers in length to prepare active drug seed crystal suspension; adding the active drug seed crystal suspension, an active drug solution and an additive solution into different channels of a coating machine, mixing and atomizing the active drug seed crystal suspension, the active drug solution and the additive solution at the nozzle tip end of the ultrasonic sprayer of the coating machine, spraying to the surface of a balloon dilatation catheter to obtain drug coating with an appropriate crystal size, and performing homogenizing post-processing to obtain the drug-coating balloon catheter with homogeneous crystals. The drug-coating balloon catheter and the production method thereof have the advantages that the drug coating is firmly combined with a balloon, and drug crystals are even and complete; small drug loss during balloon preparation and in-vivo conveying can be guaranteed, concentration of effective drugs entering the blood vessel wall of a lesion part is high, high drug loading efficiency is achieved, intravascular in-situ stenosis or restenosis can be treated effectively, the risks of late thrombosis and restenosis are reduced, and the positive remodeling of blood vessels can be formed at the same time.
Owner:LEPU MEDICAL TECH (BEIJING) CO LTD
Anti-cancer medicine composition
The present invention relates to an anticancer medicine composition and belongs to the field of medicine technology. The anticancer medicine composition contains tetrazine medicine and medicinal supplementary material. The tetrazine medicinecan inhibit intracellular DNA repair function and reduce the tolerance one tumor cell on anticancer nitrosourea medicine; and the medicine supplementary material is mainly degradable biocompatible polymer. During the degrading and absorption process of the supplementary material, the anticancer medicine is released slowly to the tumor part, and this can lower the systemic toxic reaction while maintaining local effective medicine concentration. The anticancer medicine composition contains also anticancer nitrosourea medicine, and is set to the tumor part locally to enhance the treatment effect.
Owner:广州多福医药科技有限公司
Slow-release preparation containing beta-lactamase inhibitor and its use
InactiveCN1850046AEasy to operateGood repeatabilityAntibacterial agentsAntisepticsDiseaseTreatment effect
The present invention relates to a slow-released preparation containing beta-lactamase inhibitor. Said slow-released preparation can be made into antibiotic slow-released injection or slow-released implant preparation. Said injection is formed from slow-released microsphere and solvent, said slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor with antibacterial effective dose and penicillin antibiotics, the solvent is special solvent containing suspension adjuvant of carboxymethyl cellulose sodium, etc. its viscosity is 100 cp-3000 cp (20 deg.C-30deg.C); the slow-released auxiliary material is selected from EVAc, polylactic acid copolymer, sebacic acid copolymer, albumin glue and glatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application range and can obtain obvious therapeutic effect for curing various infective diseases.
Owner:JINAN SHUAIHUA PHARMA TECH
Kitasamycin microcapsule preparation and preparation and application thereof
InactiveCN101234097AAvoid instabilityReduce instabilityAntibacterial agentsOrganic active ingredientsMedicineDrug additive
Owner:GUANGDONG HINAPHARM PHARMA CO LTD
Sustained-release injection and preparation method thereof
InactiveCN101380291APharmaceutical delivery mechanismPharmaceutical non-active ingredientsTherapeutic effectSuspending Agents
A slow release injection contains bioactive components, slow release adjuvants, a suspending agent and a dissolvant, wherein, the dissolvant is a common dissolvant or a special dissolvant containing the suspending agent. The slow release adjuvants are chosen from copolymer of polylactic acid, polyglycolic acid and hydroxyacetic acid, copolymer of ethylene vinyl acetate, polifeprosan, etc. The injection can be slowly released to the local focuses of tumors, inflammation and tuberculosis during the decomposition and absorption of the slow release adjuvants, therefore, the slow release adjuvants can not only extremely reduce general toxic reactions thereof but also keep the effective drug concentration at the chronic local focuses of tumors, etc. The suspending agent is chosen from sodium carboxymethyl cellulose, mannitol, and the like, and is used for suspending the active components or suspending the slow release particles or microspheres containing anticancer active components. The slow release injection has the advantages of good injectivity, seldom blockage, strong stability, infrequent demixing, and little general toxic reaction of local injection; furthermore, the slow release injection can selectively increase the drug concentration in local focuses, and enhance the curative effects of non-operative therapies such as radiotherapy, chemotherapy, and the like.
Owner:孔庆忠
Slow-release preparation containing macrolides anti biotics
InactiveCN1850045AIncrease concentrationReduce concentrationAntibacterial agentsOrganic active ingredientsDiseaseAdjuvant
The present invention relates to a slow-released preparation containing macrolide antibiotics. Said slow-released preparation is slow-released injection or slow-released implant preparation. Said injection is composed of slow-released microsphere and solvent, said slow-released microsphere contains slow-released auxiliary material and macrolide antibiotics, the solvent is special solvent containing suspension adjuvant of carboxymethyl cellulose sodium, its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C); the slow-released auxiliary material is selected from EVAc, PLA, PLGA, sebacic acid copolymer, albumin glue and golatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application method, and can obtain obvious therapeutic effect for curing various infective diseases.
Owner:JINAN KANGQUAN PHARMA TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com